


GUT ZOOMER 3.0



Which Patients Need the Gut Zoomer?

Conditions and symptoms associated with intestinal dysbiosis and microbiome imbalance include:

- ❑ Autoimmune conditions
- ❑ Inflammatory Bowel Disease (Crohn's and ulcerative colitis)
- ❑ Irritable Bowel Syndrome
- ❑ Celiac disease
- ❑ Cardiovascular disease
- ❑ Metabolic syndrome
- ❑ Diabetes
- ❑ Liver and gallbladder disease
- ❑ Neurological disorders
- ❑ Mood abnormalities
- ❑ Skin rashes (eczema or dermatitis)
- ❑ Inflammatory symptoms
- ❑ Small intestinal bacterial overgrowth (SIBO)
- ❑ Fatigue
- ❑ Gas and bloating
- ❑ Indigestion
- ❑ Infections
- ❑ Intestinal permeability ('leaky gut syndrome')
- ❑ Nutrient deficiencies
- ❑ GERD
- ❑ Food sensitivities
- ❑ Malnutrition



Facts About Microbiome Imbalance

Examining the entire ecosystem in the human gut can be challenging, but Vibrant Wellness has created a test that can measure **hundreds** of species of microbes at once, alongside functional markers of digestion and inflammation - providing the most comprehensive digestive health test on the market.

With over 170 species of bacteria measured, the Gut Zoomer can aid advanced practitioners in detecting **root causes** of acute or chronic illness that stem from the gastrointestinal tract, with correlations to disease states and health risks to guide primary and secondary interventions.

The Gut Zoomer also includes a robust panel of pathogenic bacteria, yeast, viruses, and parasites that are known to cause **serious health concerns** in humans.





Clinical Connections

Testing methods for the intestinal microbiome can be costly and time-consuming. Moreover, accurately measuring levels of various microbes can be challenging due to sample stability, culture techniques, sensitivity of a platform, human error, and more.

Additionally, direct population counts can vary widely from person to person, meaning that this may not be a very useful measurement altogether.

Vibrant's propriety silicon microarray technology reduces error, enhances sensitivity and specificity, and provides the most accurate measure of the *relative abundance* of an organism in the intestinal microbiome.

The Vibrant Microarray Hybridization platform is able to identify and measure the *entire DNA* from all microorganisms tested, including but not limited to the 16s and 23sRNA regions, using complementary base pairs on our microchip, which greatly expands the unique pieces of genetic material from each organism we are able to identify. This allows the Vibrant platform to achieve an unheard of level of sensitivity and specificity, especially with detection of pathogens.

Due to this heightened capacity to detect and differentiate very closely related species, Vibrant's laboratory testing for microorganisms, such as the Gut Zoomer, can accurately detect and report these microorganisms that are often erroneously reported as pathogens by other less sensitive platforms, despite being similar, but not the same species.

Vibrant does not use sequencing technology to detect microorganism genetic material, due to the limitations of sensitivity and specificity inherent to that type of platform.




67 Pathogenic Microorganisms, including Bacteria, Fungi, Parasites, and Viruses:

- ✓ Clostridium
- ✓ EPEC, ETEC, STEC, and EAEC
- ✓ E coli 0157
- ✓ H pylori
- ✓ Listeria
- ✓ K pneumoniae
- ✓ Edwardsiella tarda
- ✓ Campylobacter

- ✓ Yersinia
- ✓ Salmonella
- ✓ Cryptosporidium
- ✓ E histolytica
- ✓ Giardia
- ✓ Cyclospora
- ✓ Entamoeba
- ✓ Vibrio

- ✓ Nematodes
- ✓ Schistoma
- ✓ Blastocystis
- ✓ Trichomonas
- ✓ Viruses
- ✓ Candida

And many more!



Regulatory Statement

The general wellness test intended uses relate to sustaining or offering general improvement to functions associated with a general state of health while making reference to diseases or conditions. This test has been laboratory developed and its performance characteristics determined by Vibrant Genomics LLC, a CLIA-certified laboratory performing the test. The test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.